GlassScriptPhysician profile
William B Flores
NPI 1942530571
$93,658.64
in general payments reported to CMS, 2019-2025
67 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,387 · 2022: $9,278 · 2023: $21K · 2024: $32K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $21K · Travel and Lodging: $16K · Education: $42.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,738.97 |
| Food and Beverage | $21,005.78 |
| Travel and Lodging | $16,206.56 |
| Education | $42.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $60,542.79 | 2021-2025 | Descovy, Yeztugo, Biktarvy |
| Viiv Healthcare Company | $8,949.65 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Napo Pharmaceuticals INC | $6,540.42 | 2021-2025 | Mytesi |
| Merck Sharp & Dohme LLC | $3,862.83 | 2021-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Emd Serono, INC. | $1,647.84 | 2021-2025 | Serostim, Serostim |
| Amgen INC. | $1,183.27 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $1,056.81 | 2021-2025 | |
| Novo Nordisk INC | $933.35 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Biotech, INC. | $795.57 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $748.57 | 2021-2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $563.58 | 2022-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $429.92 | 2023-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $429.24 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $387.25 | 2022-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $380.10 | 2021-2025 | Trintellix |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $375.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $337.59 | 2022-2025 | Dupixent |
| Antares Pharma, INC. | $336.40 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.25 | 2021-2025 | Xifaxan, Relistor |
| Bausch Health US, LLC | $313.44 | 2021-2025 | Aplenzin |
| Nestle Healthcare Nutrition INC. | $299.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $204.50 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Aimmune Therapeutics, INC. | $201.33 | 2024-2025 | Zenpep |
| Angiodynamics, INC. | $196.55 | 2025 | Angiovac |
| Horizon Therapeutics Plc | $166.77 | 2021-2023 | Krystexxa |
| Janssen Products, LP | $148.95 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $140.78 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.45 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $132.61 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dynavax Technologies Corporation | $132.06 | 2021-2022 | |
| Corium, LLC | $121.35 | 2024 | Azstarys |
| Argenx US, INC. | $115.38 | 2024-2025 | Vyvgart Hytrulo |
| Halozyme INC | $113.67 | 2023 | |
| Exact Sciences Corporation | $110.77 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $110.14 | 2021 | |
| Eisai INC. | $100.46 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $91.16 | 2021-2025 | Nexletol, Contrave, Onzetra Xsail |
| Biohaven Pharmaceutical Holding Company LTD. | $88.42 | 2022 | |
| Phathom Pharmaceuticals, INC. | $74.33 | 2024 | Voquezna |
| Alk-Abello, INC | $50.24 | 2025 | Neffy, Odactra, Grastek |
| Hologic Sales and Service, LLC | $49.05 | 2024 | Aptima |
| Amarin Pharma, INC. | $47.58 | 2022 | |
| Biogen, INC. | $42.35 | 2024-2025 | Skyclarys |
| Harmony Biosciences LLC | $41.14 | 2022 | |
| Shield Therapeutics INC | $36.96 | 2022 | |
| Tolmar, INC. | $36.95 | 2025 | Jatenzo |
| Ars Pharmaceuticals Operations, INC. | $35.21 | 2025 | Neffy |
| Clarus Therapeutics INC. | $34.54 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.29 | 2025 | Ultomiris |
| Grt US Holding, INC. | $34.29 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.76 | 2025 | Fanapt |
| Genentech USA, INC. | $31.55 | 2025 | Ocrevus Zunovo |
| Endo Pharmaceuticals INC. | $30.73 | 2021 | |
| Boston Scientific Corporation | $29.27 | 2022 | |
| Lundbeck LLC | $28.88 | 2025 | Vyepti |
| Alkermes, INC. | $25.85 | 2024 | Lybalvi |
| Irhythm Technologies, INC. | $25.74 | 2023 | Zio Xt Patch |
| Redhill Biopharma INC. | $24.84 | 2021 | |
| Ge Healthcare | $23.55 | 2025 | |
| Optos, INC. | $20.01 | 2021 | |
| Seqirus USA INC | $18.93 | 2022 | |
| Virtus Pharmaceuticals LLC | $18.07 | 2024 | Levorphanol Tartrate |
| Azurity Pharmaceuticals, INC. | $16.33 | 2024 | Horizant |
| Kowa Pharmaceuticals America, INC. | $16.06 | 2023 | Seglentis |
| Acerus Pharmaceuticals Corporation | $15.89 | 2022 | |
| Abbott Laboratories | $14.60 | 2025 | Eterna |
| Arbor Pharmaceuticals, INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.